ZODIAC: A Risk-based Decision Support System Did Not Significantly Improve Lipid-Lowering vs Usual Care
Key Points Maximizing lipid lowering therapy (LLTs) to optimize residual cardiovascular disease…
Exenatide, a GLP-1 Analog, Did Not Reduce Organ Injury, Stroke or Death During Cardiac Surgery: GLORIOUS Trial
KEY POINTS: Exenatide is a glucaon-like-peptide-1 agonist (GLP-1) improves glycemic control, and…
Plozasiran Showed Sustained Reductions in TG in Familial Chylomicronemia Syndrome: PALISADE Trial
Key Points: Familial chylomicronemia syndrome (FCS) is characterized by extremely high plasma…
Catheter Ablation Better Than Antiarrhythmic Drugs for VT in Ischemic Cardiomyopathy With ICD: VANISH2 Trial
Key Takeaways: The VANISH2 trial compared catheter ablation with systematic antiarrhythmic drug…
CLEAR SYNERGY: No Benefit with Routine Spironolactone in MI Patients
Key Takeaways: The CLEAR SYNERGY trial was a multicenter trial with a…
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran Associated with Durable Reductions in Serum TTR levels for ATTR -CM
Key Takeaways: A single dose of nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based therapy,…
SUMMIT: Tirzepatide Decreased The Risk Of Worsening HF And CV Death in HFpEF + Obesity
Key Points SUMMIT was a multi-national trial that compared cardiovascular outcomes among…
BPROAD: Intensive Blood Pressure Target Reduces MACE in Type 2 Diabetes
Key Points BPROAD was a randomized control trial in China that assigned…
Rivaroxaban Did Not Reduce Cognitive Decline and Stroke/TIA in Young AF Patients: BRAIN-AF Trial
Key Points: In patients with atrial fibrillation, it remains unclear if anticoagulation…
QFR Did Not Meet Non-inferiority to FFR: FAVOR III Europe Trial
The FAVOR III Europe study aimed to investigate whether a QFR-based diagnostic…
Orbital Atherectomy No Benefit Over Conventional Ballon Dilatation in Calcified Lesions: ECLIPSE Trial
The ECLIPSE trial evaluated orbital atherectomy (OA) vs conventional balloon dilatation (BA)…
No Benefit of Colchicine in Large MIs: CLEAR SYNERGY Trial
Several randomized trials have shown reductions in MACE with colchicine in the…
ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction
KEY POINTS: In this prespecified exploratory analysis of the AEGIS-II trial, the…
Apolipoprotein A-I infusions Lowers Risk of Recurrent CV Events in Patients With Baseline LDL-C ≥100 mg/dL
KEY POINTS: In this exploratory analysis of the AEGIS-II randomized control trial,…
Improved Accuracy of HF Diagnosis with HFDetect-AI
Key Points: HFDetect-AI significantly improves the accuracy of diagnosing heart failure by…
Pre-Hospital Pulse-Dose Glucocorticoid Did not Reduce Infarct Size in STEMI: PULSE-MI
Key Points: The PULSE-MI trial assessed the effects of pre-hospital pulse-dose glucocorticoid…
ECLS-SHOCK: At One Year, ECMO Does Not Reduce Mortality in Acute MI-Related Cardiogenic Shock
Key Points: The 30-day ECLS SHOCK study demonstrated no benefit to up-front…
REC-CAGEFREE I: Drug Coated Balloon Fails To Achieve Non-Inferiority vs DES For De Novo Coronary Lesions
Key Points Drug-eluting stents are the standard of care for percutaneous coronary…
Plozasiran Lowered Triglyceride Levels and Pancreatitis in Persistent Chylomicronemia: PALISADE
Key Points: Familial chylomicronemia syndrome (FCS) is a clinically or genetically defined…
Bailout GP IIb/IIIa inhibition in AMI with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO: The REVERSE-FLOW trial
Key Points: Though primary PCI for coronary obstruction is first-line therapy in…